Free serum IgE suppression with omalizumab and clinical outcomes in asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Monitoring free serum IgE in asthma patients treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Relationship between pre-treatment specific IgE and the response to omalizumab therapy Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Quantitative IgE levels in asthma and implications for treatment with omalizumab. Are the cutoffs to narrow? Source: Annual Congress 2011 - Asthma management and response Year: 2011
Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Correlation between specific serum IgE and exhaled NO levels at low and high inhaled corticosteroid use in allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 276s Year: 2005
Effect of montelukast administration on serum IL-5 and total IgE levels in asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 579s Year: 2004
Tolerability assessment of a recombinant humanized monoclonal anti-IgE antibody (omalizumab) as a treatment for seasonal allergic rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 116s Year: 2002
A regression equation for the conversion of plasma IgE to serum IgE in patients with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 110s Year: 2003
Elevated serum IgE, oral corticosteroid dependence and IL-17/22 expression in highly neutrophilic asthma Source: Eur Respir J, 54 (5) 1900068; 10.1183/13993003.00068-2019 Year: 2019
Patient characteristics that can predict response to omalizumab an (anti-IgE antibody) for achieving better control of asthmatic patients Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002
The influence of the allergen-specific immunotherapy (ASIT) against the backdrop of an immunomodulator in patients suffering from seasonal allergic rhinitis (SAR) on the level of cytokines, IgE and IgG. Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020
Evaluating response to omalizumab (anti-IgE) in clinical practice Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Improved disease control in asthmatics treated with daclizumab is not associated with changes in allergen-specific or total IgE Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
SIT follow-up: Measurements of specific IgG and IgG4 serum levels Source: Eur Respir J 2002; 20: Suppl. 38, 507s Year: 2002
Correlation between grass pollen specific IgG,IgG4 and IgE in patients treated with SIT Source: Eur Respir J 2002; 20: Suppl. 38, 507s Year: 2002
Effect of IgE sensitization and allergen exposure on exhaled NO during inhaled corticosteroid (ICS) treatment in patients with asthma Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007
How to evaluate a patient's response to anti-IgE Source: Eur Respir Rev 2007; 16: 78-84 Year: 2007